Login to Your Account

Clinic Roundup

Thursday, September 15, 2011
Oxigene Inc., of South San Francisco, presented a retrospective comparative analysis suggesting Zybrestat (fosbretabulin) confers a one-year survival benefit in patients with anaplastic thyroid cancer (ATC) compared to treatment with chemotherapy alone. The data were collected from five Phase I and Phase II trials and from the Mayo Clinic's database.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription